SCHEMBL4653372

SCHEMBL4653372

COC(=O)C(NC(=O)O)C(C)C

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA12 O43570 2/20 0.54
CA14 Q9ULX7 2/20 0.54
TAS1R3 Q7RTX0 1/20 0.50
TAS1R1 Q7RTX1 1/20 0.50
TSHR P16473 1/20 0.47
SMN1; SMN2 Q16637 3/20 0.46
MEN1 O00255 2/20 0.45
KMT2A Q03164 2/20 0.45
CYP2C9 P11712 1/20 0.45
CYP2C19 P33261 1/20 0.45
ALDH1A1 P00352 4/20 0.44
NPSR1 Q6W5P4 1/20 0.44
MAPT P10636 1/20 0.44
HSD17B10 Q99714 1/20 0.44
CA7 P43166 1/20 0.43
CA9 Q16790 1/20 0.43
GAA P10253 2/20 0.42
THRB P10828 1/20 0.41
BIRC2 Q13490 1/20 0.41
HPGD P15428 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27293618 0.82 TSHR (0.37) CA12CA14TAS1R3TAS1R1TSHR
SCHEMBL7601776 0.82 MGAM (0.41) SMN1; SMN2ALDH1A1NPSR1MAPTHSD17B10
SCHEMBL5814134 0.81 CA12 (0.54) CA12CA14TAS1R3TAS1R1TSHR
SCHEMBL9957362 0.81 CA12 (0.54) CA12CA14TAS1R3TAS1R1TSHR
SCHEMBL5814139 0.81 CA12 (0.54) CA12CA14TAS1R3TAS1R1TSHR
SCHEMBL7607226 0.81 CA12 (0.54) CA12CA14TAS1R3TAS1R1TSHR
SCHEMBL13286492 0.80 SMN1; SMN2 (0.50) CA12CA14SMN1; SMN2MEN1KMT2A
SCHEMBL13530964 0.80 SMN1; SMN2 (0.50) CA12CA14SMN1; SMN2MEN1KMT2A
SCHEMBL13286279 0.80 SMN1; SMN2 (0.50) CA12CA14SMN1; SMN2MEN1KMT2A
SCHEMBL13286136 0.80 SMN1; SMN2 (0.50) CA12CA14SMN1; SMN2MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1212295-B1 SUBSTITUTED ALPHA-HYDROXY ACID CASPASE INHIBITORS AND THE USE THEREOF CYTOVIA INC (US) 2008-10-01 EP claimed
EP-1494700-A2 CASPASE INHIBITORS FOR THE TREATMENT OF DISEASES AND CONDITIONS CAUSED BY EXPOSURE TO RADIONUCLIDES, BIOLOGICAL AGENTS, OR CHEMICAL AGENTS Cytovia, Inc. (US) 2005-01-12 EP claimed
WO-2004002401-A2 CASPASE INHIBITORS FOR THE TREATMENT OF DISEASES AND CONDITIONS CAUSED BY EXPOSURE TO RADIONUCLIDES, BIOLOGICAL AGENTS, OR CHEMICAL AGENTS CYTOVIA, INC. (US) 2004-01-08 WO claimed
WO-2014163643-A1 GGA AND GGA DERIVATIVES COMPOSITIONS THEREOF AND METHODS FOR TREATING NEURODEGENERATIVE DISEASES INCLUDING PARALYSIS INCLUDING THEM COYOTE PHARMACEUTICALS, INC. (US) 2014-10-09 WO disclosed
WO-2014151719-A1 SUBLINGUAL FORMULATIONS INCLUDING GERANYLGERANYLACETONE AND GERANYLGERANYLACETONE DERIVATIVES COYOTE PHARMACEUTICALS, INC. (US) 2014-09-25 WO disclosed